{
      "Rank": 443,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive EN001 intravenously (IV) once on Day 0.",
            "Participants will receive EN001 intravenously (IV) once on Day 0."
      ],
      "ArmGroupInterventionName": [
            "Drug: EN001",
            "Drug: EN001"
      ],
      "ArmGroupLabel": [
            "Dose group A (Low dose)",
            "Dose group B (High dose)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05333406"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Charcot-Marie-Tooth disease (CMT) type 1A"
      ],
      "BriefTitle": [
            "Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2027"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Charcot-Marie-Tooth Disease, Type IA"
      ],
      "ConditionAncestorId": [
            "D000009057",
            "D000009421",
            "D000009422",
            "D000020271",
            "D000019636",
            "D000011115",
            "D000010523",
            "D000009468",
            "D000000013",
            "D000030342"
      ],
      "ConditionAncestorTerm": [
            "Stomatognathic Diseases",
            "Nervous System Malformations",
            "Nervous System Diseases",
            "Heredodegenerative Disorders, Nervous System",
            "Neurodegenerative Diseases",
            "Polyneuropathies",
            "Peripheral Nervous System Diseases",
            "Neuromuscular Diseases",
            "Congenital Abnormalities",
            "Genetic Diseases, Inborn"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "All",
            "BC07",
            "BC16",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "All Conditions",
            "Mouth and Tooth Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Charcot-Marie-Tooth Disease",
            "Tooth Disease",
            "Charcot-Marie-Tooth Disease",
            "Charcot-Marie-Tooth Disease",
            "Charcot-Marie-Tooth Disease",
            "Charcot-Marie-Tooth Disease",
            "Charcot-Marie-Tooth Disease",
            "Charcot-Marie-Tooth Disease"
      ],
      "ConditionBrowseLeafId": [
            "M11504",
            "M15983",
            "M5005",
            "M17244",
            "M15507",
            "M11169",
            "M12",
            "M11517",
            "M21245",
            "M20711",
            "M13151",
            "M12584",
            "M11563",
            "M22839",
            "T1081",
            "T2761",
            "T2766",
            "T5067"
      ],
      "ConditionBrowseLeafName": [
            "Nerve Compression Syndromes",
            "Tooth Diseases",
            "Charcot-Marie-Tooth Disease",
            "Hereditary Sensory and Motor Neuropathy",
            "Syndrome",
            "Stomatognathic Diseases",
            "Congenital Abnormalities",
            "Nervous System Malformations",
            "Heredodegenerative Disorders, Nervous System",
            "Neurodegenerative Diseases",
            "Polyneuropathies",
            "Peripheral Nervous System Diseases",
            "Neuromuscular Diseases",
            "Genetic Diseases, Inborn",
            "Charcot-Marie-Tooth Disease",
            "Hereditary Motor and Sensory Neuropathy",
            "Hereditary Neuropathy With Liability to Pressure Palsies",
            "Roussy Levy Syndrome"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000014076",
            "D000002607",
            "D000009408",
            "D000015417"
      ],
      "ConditionMeshTerm": [
            "Tooth Diseases",
            "Charcot-Marie-Tooth Disease",
            "Nerve Compression Syndromes",
            "Hereditary Sensory and Motor Neuropathy"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "It is the first in human (FIH), 3+3 design clinical trial to evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMales and females aged 19 to 75 years old\nThose diagnosed with CMT type 1A by a genetic test\nThose whose CMTNS-v2 score is more than 2 and 20 or fewer points, and the severity of the disease is mild to moderate\nThose who have dorsiflexion muscle weakness\nThose who can comply with the requirements for clinical trials\nFor women of childbearing potential, those who have a negative urine pregnancy test at screening\nThose who use a medically acceptable method of contraception until clinical trial visit 7 (short-term follow-up visit, 16 weeks): hormonal contraception, intrauterine device (IUD), intrauterine system (IUS), vasectomy, tubal ligation, or double barrier method using a cervical cap or a diaphragm with a male condom.\nThose who voluntarily agree to participate in this study and sign an IRB-approved consent form after being informed about the characteristics of this clinical trial prior to all screening tests\n\nExclusion Criteria:\n\nThose with other neuromuscular diseases that the investigator judges cannot participate in the clinical trial\nPatients diagnosed with type 1 or type 2 diabetes\nThose with a history of stroke or cerebral ischemic attack within 12 months of screening\nThose with a history of coronary artery diseases such as myocardial infarction or unstable angina within 12 months of screening\nThose who have undergone orthopedic surgery on the lower extremities (bone and ligament correction, artificial joint insertion, osteotomy, arthroscopic surgery) within 6 months of screening\nThose who have ankle contractures or have surgery that may affect muscle strength assessment\nThose who have experience with stem cell therapy or gene therapy before screening\nThose who have participated in clinical trials for chemical synthetic drugs before screening (except when 5 times the half-life has passed)\nPatients with uncontrolled hypertension (If the systolic blood pressure is 180 mmHg or higher or the diastolic blood pressure is 110 mmHg or higher)\nIf there is a history of malignant tumors other than basal cell carcinoma or squamous cell carcinoma occurring in the skin within 5 years of screening\nThose who diagnosed with active pulmonary tuberculosis\nImmunosuppressed patients who are taking immunosuppressants, chemotherapy, radiation therapy, etc.\nMental illness patients\nThose who are pregnant or lactating\nThose with significant heart, lung, liver, kidney, hematological, immunological, behavioral disease, or other clinically significant diseases including malignant tumors\nThose who have a previous or current medical condition that may adversely affect the safety of the subject, make it difficult to complete treatment or affect the evaluation of clinical trial results at the discretion of the investigator\nThose who do not have the will or ability to comply with clinical trial procedures at the discretion of the investigator"
      ],
      "EnrollmentCount": [
            "12"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Dose group A (Low dose)",
            "Dose group B (High dose)"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.\n\nDose group A (Low dose): 5.0x10^5 cells/kg",
            "EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.\n\nDose group B (High dose): 2.5x10^6 cells/kg"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "EN001",
            "EN001"
      ],
      "InterventionOtherName": [
            "EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)",
            "EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 13, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 12, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "ENCell"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Seoul"
      ],
      "LocationContactEMail": [
            "encell@encellinc.com"
      ],
      "LocationContactName": [
            "ENCell Co., Ltd."
      ],
      "LocationContactPhone": [
            "+82-2-6205-8040"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "Korea, Republic of"
      ],
      "LocationFacility": [
            "Samsung Medical Center"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "19 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "ENCell"
      ],
      "OrgStudyId": [
            "ENCell_2020_02"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 20, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Number of participants with treatment-related AEs/SAEs as assessed by CTCAE v5.0",
            "Among the adverse events occurring for 4 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE v5.0",
            "Among the adverse events occurring for 4 weeks after administration of the investigational product, Grade 3 or higher adverse events according to CTCAE v5.0 Maximum tolerated dose defines the evaluated maximum dose level in which greater than two participants of six participants experience Dose-limiting toxicity (DLT) under the dose level. The dose level where two participants of six participants experience DLT will be the maximum tolerated dose.",
            "Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (\u2103) and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001.\n\nThe number of participants with at least one potentially clinically significant abnormal vital sign finding were reported as treatment emergent adverse events (TEAEs).",
            "Physical Examinations include general appearance, head, ears/eyes/nose/throat, cardiovascular, respiratory, abdomen, skin, lymph nodes, extremities, musculoskeletal and neurologic and will be assessed by CTCAE v 5.0 to evaluate safety and tolerability of EN001.\n\nNumber of participants with potentially clinically significant abnormalities in physical examinations were reported as TEAEs.",
            "Laboratory Parameters include hematology, chemistry laboratory tests, urinalysis, coagulation test and plasma viral load test and will be assessed by CTCAE 5.0 to evaluate safety and tolerability of EN001.\n\nNumber of participants with at least one potentially clinically significant abnormal finding were reported as TEAEs.",
            "Measured by result of the ECG measurements and findings"
      ],
      "PrimaryOutcomeMeasure": [
            "Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product",
            "Determination of Dose-limiting toxicity (DLT) levels of EN001",
            "Determination of Maximum tolerated dose (MTD) levels of EN001",
            "Number of participants with Vital Signs abnormalities",
            "Number of participants with clinically significant abnormalities of Physical Examinations",
            "Number of participants with abnormalities of Laboratory Parameters",
            "Number of participants with 12-lead Electrocardiography (ECG) abnormalities"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Week 16 after treatment",
            "Up to Week 4 after dosing on Day 0",
            "Up to Week 4 after dosing on Day 0",
            "From screening up to Week 16",
            "From screening up to Week 16",
            "From screening up to Week 16",
            "From screening to baseline on Day 1 (Predose to end of infusion and 90 min after completion of infusion)"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Occurrence of any adverse reactions, development of new blood clots, tumors, immune responses (like autoimmune reactions) and death, and/or serious adverse events related investigational product will be summarized by actual treatment groups respectively.",
            "Abnormalities of Vital Signs, Physical Findings, and Laboratory parameters (as described above) will be collected and analyzed, and then assessed by CTCAE 5.0 to evaluate the long-term safety of EN001.",
            "Disease severity measured by CMTNS-v2 score will be collected and analyzed to evaluate the exploratory efficacy of EN001.",
            "Gait and balance functions measured by Ten Meter Walking Test(10MWT), Functional Disability Scale (FDS), and Overall Neuropathy Limitation Score (ONLS) leg scale will be collected and analyzed to evaluate the exploratory efficacy of EN001.",
            "The degree of muscle damage measured by lower extremity magnetic resonance imaging (MRI) scan will be collected and analyzed to evaluate the exploratory efficacy of EN001.",
            "Nerve generation potential measured by MNCV, SNCV, CMAP, and SNAP will be collected and analyzed to evaluate the exploratory efficacy of EN001."
      ],
      "SecondaryOutcomeMeasure": [
            "Incidence of adverse events (AEs)",
            "Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters",
            "Change from baseline in disease severity CMTNS-v2 score",
            "Change from baseline in gait and balance functions",
            "Change from baseline in the degree of muscle damage (%)",
            "Change from baseline in nerve regeneration potential"
      ],
      "SecondaryOutcomeTimeFrame": [
            "From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)",
            "From screening to the end of treatment/withdrawal visit (up to approximately 5 years per subject)",
            "Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)",
            "Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)",
            "Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)",
            "Screening and baseline on Day 0 (up to approximately 5 years per subject after Week 4)"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "February 22, 2022"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "May 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 19, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "January 6, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "April 11, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}